Publication Name	World Journal of Gastroenterology
Manuscript ID	79690
Country	Japan

Received	2022-09-02 08:27
Peer-Review Started	2022-09-02 08:33
To Make the First Decision
Return for Revision	2022-10-20 18:37
Revised	2022-11-07 12:42
Second Decision	2022-12-07 03:23
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2022-12-07 17:16
Articles in Press	2022-12-07 17:16
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2022-12-20 23:59
Publish the Manuscript Online	2022-12-27 10:06

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	COVID-19 vaccination and liver disease
Manuscript Source	Invited Manuscript
All Author List	Sotaro Ozaka, Takashi Kobayashi, Kazuhiro Mizukami and Kazunari Murakami
ORCID	Author(s) ORCID Number Sotaro Ozaka http://orcid.org/0000-0002-6283-7012 Takashi Kobayashi http://orcid.org/0000-0002-9069-5736 Kazuhiro Mizukami http://orcid.org/0000-0002-3148-8884 Kazunari Murakami http://orcid.org/0000-0003-2668-5039
Funding Agency and Grant Number
Corresponding Author	Sotaro Ozaka, MD, PhD, Assistant Professor, Department of Gastroenterology, Faculty of Medicine, Oita University, 1-1 Idaigaoka, Hasama, Yufu 879-5593, Oita, Japan. ozakaso@oita-u.ac.jp
Key Words	COVID-19 vaccine; Liver disease; Side effect; Liver injury; Immune-related hepatitis; Autoimmune hepatitis
Core Tip	Patients with chronic liver disease (CLD), including cirrhosis, are a high-risk group for severe coronavirus disease 2019 (COVID-19). Presently, the results of several clinical trials for measuring the efficacy and safety of the available COVID-19 vaccines in patients with CLD have been reported. Given the increased rates of severity and mortality of COVID-19 in patients with CLD, the importance of aggressive vaccination in the effective management of severe acute respiratory syndrome coronavirus 2 infection should be emphasized. Although liver injury following COVID-19 vaccination has also been reported, it is infrequent and is not a factor in vaccine hesitancy.
Publish Date	2022-12-27 10:06
Citation	Ozaka S, Kobayashi T, Mizukami K, Murakami K. COVID-19 vaccination and liver disease. World J Gastroenterol 2022; 28(48): 6791-6810
URL	https://www.wjgnet.com/1007-9327/full/v28/i48/6791.htm
DOI	https://dx.doi.org/10.3748/wjg.v28.i48.6791

Full Article (PDF)	WJG-28-6791.pdf
Full Article (Word)	WJG-28-6791.docx
Manuscript File	79690_Auto_Edited-LM.docx
Answering Reviewers	79690-Answering reviewers.pdf
Audio Core Tip	79690-Audio core tip.mp4
Conflict-of-Interest Disclosure Form	79690-Conflict-of-interest statement.pdf
Copyright License Agreement	79690-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	79690-Language certificate.pdf
Peer-review Report	79690-Peer-review(s).pdf
Scientific Misconduct Check	79690-Bing-Fan JR-2.png
Scientific Editor Work List	79690-Scientific editor work list.pdf